文献速递炎症性肠病

戈利木单抗强化治疗溃疡性结肠炎的有效性:一项多中心前瞻性研究

Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study.
PubMed 文献 · Aliment Pharmacol Ther · 2023-02-27

这项多中心前瞻性队列研究纳入47例对戈利木单抗失去应答的活动性溃疡性结肠炎患者,分别将50 mg每4周或100 mg每4周强化为100 mg每4周或100 mg每2周。强化后第4-8周约44%患者获临床应答、22%获临床缓解;强化前血清戈利木单抗水平未预测应答,强化至100 mg每4周与第3次访视时临床缓解显著相关(OR 1.98,95%CI 1.06-3.70;P=0.032)。

要点

  • 约半数溃疡性结肠炎患者戈利木单抗强化后重获应答。
  • 强化前血清戈利木单抗水平未预测临床或内镜应答/缓解。
  • 强化至100 mg每4周与临床缓解显著相关(OR 1.98,95%CI 1.06-3.70)。

核心结论

  • 在这项前瞻性多中心研究中,半数溃疡性结肠炎患者戈利木单抗强化后重获应答。
  • 治疗药物监测未预测戈利木单抗优化后的应答。

研究设计与样本

  • 前瞻性多中心队列研究,连续纳入47例对戈利木单抗失去应答的活动性溃疡性结肠炎患者。
  • 50 mg每4周失去应答者强化至100 mg每4周,100 mg每4周失去应答者强化至100 mg每2周。
  • 强化后第2-4周(第2次访视)和第4-8周(第3次访视)评估有效性与安全性,每次访视检测血清药物水平和抗戈利木单抗抗体。

主要发现

  • 患者女性占50%,中位年龄39岁(IQR 27-52),戈利木单抗中位治疗20.4周(IQR 10.7-38.3)。
  • 基线中位部分Mayo评分6分(IQR 5-7),中位内镜Mayo评分3分(IQR 2-3)。
  • 强化前中位戈利木单抗血清水平2.23 μg/mL(IQR 1.02-3.96),仅1例(2.1%)有抗药物抗体。
  • 第2次访视(第2-4周):40%患者临床应答,10%临床缓解,33%内镜应答,23%内镜缓解。
  • 第3次访视(第4-8周):44%患者临床应答,22%临床缓解,45%内镜应答,41%内镜缓解。

关键数值与推荐

  • 强化至100 mg每4周(对比每2周)与第3次访视时临床缓解显著相关(OR 1.98,95%CI 1.06-3.70;P=0.032)。
  • 基线血清药物水平或抗药物抗体存在与临床或内镜缓解/应答均不相关。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Loss of response to golimumab occurs in nearly 40% of patients with ulcerative colitis (UC). Unlike others anti-TNF, no study has reported a correlation between serum golimumab level and response to drug intensification. The objective of this study was to evaluate the effectiveness and safety of golimumab intensification and to identify the best threshold of serum golimumab before drug intensification predictive of response. PATIENTS AND METHODS: We included all consecutive patients with active UC with loss of response to golimumab in a prospective multicentric cohort study. Patients with loss of response at 50 mg q4 weeks (W) and 100 mg q4W underwent therapeutic intensification at 100 mg q4W and 100 mg q2W, respectively. Effectiveness and safety were assessed between Weeks 2 and 4 (visit 2) and between Weeks 4 and 8 (visit 3) after intensification. Serum level and anti-golimumab antibodies were evaluated at each medical visit (Lisa Tracker, Theradiag France). RESULTS: A total of 47 UC patients (Female, 50%; median age, 39 years (IQR, 27-52)) treated with golimumab for a median of 20.4 weeks (IQR, 10.7-38.3) were included. The median partial Mayo score was 6 (IQR, 5-7), and the median endoscopic Mayo score was 3 (IQR, 2-3). The median golimumab serum level before intensification was 2.23 μg/mL (IQR, 1.02-3.96) and only one patient (2.1%) had anti-drug antibodies. At Visit 2 (Week 2-4), 40% patients experienced clinical response, 10% clinical remission, 33% endoscopic response and 23% endoscopic remission. At Visit 3 (Week 4-8), 44% of patients had clinical response, 22% of patients had clinical remission, 45% of patients had endoscopic response, and 41% of patients had endoscopic remission. The median golimumab levels before intensification do not differ between responders and non-responders (2.13 μg/ml (0.76-2.76) and 3.37 μg/ml (IQR, 1.08-4.67), respectively; p = 0.14) assessed at Visit 3. Golimumab intensification to 100 mg q4W (vs q2W) (OR 1.98, 95% CI [1.06-3.70]; p = 0.032) was significantly associated with clinical remission at Visit 3. Serum drug level at baseline or the presence of antidrug antibodies were not associated with clinical or endoscopic remission/response. Two serious adverse events (one infection and one UC flare) were reported during the 24-week follow-up. CONCLUSION: In this prospective multicentric study, half of patients recaptured response following golimumab intensification in UC. Therapeutic drug monitoring did not predict response after optimisation of golimumab.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Fumery M, Nancey S, Filippi J, et al. Effectiveness of golimumab intensification in ulcerative colitis: A multicentric prospective study. Aliment Pharmacol Ther. 2023. PMID: 36849714. doi:10.1111/apt.17421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。